An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE).
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2014
At a glance
- Drugs Paquinimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Biomarker; Therapeutic Use
- 26 May 2011 Results have been presented at EULAR-2011 according to an Active Biotech AB media release.
- 19 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2010 An update on this trial will be presented at the UBS Global Life Sciences Conference, September 2010, according to an Active Biotech media release.